0001737287-19-000022 Sample Contracts

INDENTURE Dated as of [•], 20__ Debt Securities
Indenture • November 5th, 2019 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York

INDENTURE, dated as of [•], 20__, among Allogene Therapeutics, Inc., a Delaware corporation (the “Company”), and [TRUSTEE], as trustee (the “Trustee”):

Sample 1Sample 2Sample 3See All (492)
AutoNDA by SimpleDocs
ALLOGENE THERAPEUTICS, INC. AND _____________, AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF __________
Common Stock Warrant Agreement • November 5th, 2019 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York

THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between Allogene Therapeutics, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).

Sample 1Sample 2Sample 3See All (268)
ALLOGENE THERAPEUTICS, INC. AND _____________, AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF __________
Preferred Stock Warrant Agreement • November 5th, 2019 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York

THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between Allogene Therapeutics, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).

Sample 1Sample 2Sample 3See All (200)
ALLOGENE THERAPEUTICS, INC. AND _____________, AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF __________
Securities Warrant Agreement • November 5th, 2019 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York

THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between Allogene Therapeutics, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).

Sample 1Sample 2Sample 3See All (87)
ALLOGENE THERAPEUTICS, INC. $250,000,000 COMMON STOCK SALES AGREEMENT
Allogene Therapeutics, Inc. • November 5th, 2019 • Biological products, (no disgnostic substances) • New York

Allogene Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:

Sample 1Sample 2Sample 3See All (24)
Time is Money Join Law Insider Premium to draft better contracts faster.